Ftse Mib
37.242,17
0,50%
DAX
21.911,74
0,68%
S&P 500
6.061,05
0,58%
NASDAQ
19.707,38
0,94%
Bitcoin
97.270,18
0,81%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NuCana PLC (NCNA) NuCana PLC (NCNA) Notizie

NCNA

NuCana (NCNA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NCNA
DataOraFonteTitoloSimboloCompagnia
10/02/202514:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NCNANuCana PLC
25/11/202413:00GlobeNewswire Inc.NuCana Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NCNANuCana PLC
11/11/202413:00GlobeNewswire Inc.NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or DocetaxelNASDAQ:NCNANuCana PLC
01/10/202412:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NCNANuCana PLC
25/09/202422:01GlobeNewswire Inc.NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United StatesNASDAQ:NCNANuCana PLC
14/09/202409:01GlobeNewswire Inc.NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024NASDAQ:NCNANuCana PLC
29/08/202422:01GlobeNewswire Inc.NuCana Announces Update for Phase 2 Randomized Colorectal Cancer StudyNASDAQ:NCNANuCana PLC
15/08/202422:35Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:NCNANuCana PLC
15/08/202422:01GlobeNewswire Inc.NuCana Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NCNANuCana PLC
30/05/202414:36GlobeNewswire Inc.NuCana to Present at the Jefferies Global Healthcare ConferenceNASDAQ:NCNANuCana PLC
21/05/202414:00GlobeNewswire Inc.NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation SummitNASDAQ:NCNANuCana PLC
16/05/202422:01GlobeNewswire Inc.NuCana Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NCNANuCana PLC
01/05/202422:01GlobeNewswire Inc.NuCana Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:NCNANuCana PLC
16/04/202414:00GlobeNewswire Inc.NuCana Announces Completion of ADS Ratio ChangeNASDAQ:NCNANuCana PLC
09/04/202422:30GlobeNewswire Inc.NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical StudyNASDAQ:NCNANuCana PLC
27/03/202421:30GlobeNewswire Inc.NuCana Announces Plan to Implement ADS Ratio ChangeNASDAQ:NCNANuCana PLC
20/03/202421:01GlobeNewswire Inc.NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business UpdateNASDAQ:NCNANuCana PLC
27/02/202414:00GlobeNewswire Inc.NuCana to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:NCNANuCana PLC
06/02/202414:00GlobeNewswire Inc.NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:NCNANuCana PLC
16/11/202322:01GlobeNewswire Inc.NuCana Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NCNANuCana PLC
10/11/202322:01GlobeNewswire Inc.NuCana Announces Listing Transfer to Nasdaq Capital MarketNASDAQ:NCNANuCana PLC
08/11/202322:01GlobeNewswire Inc.NuCana to Present at the Jefferies London Healthcare ConferenceNASDAQ:NCNANuCana PLC
01/11/202321:01GlobeNewswire Inc.NuCana to Participate in the Truist Securities 2023 BioPharma SymposiumNASDAQ:NCNANuCana PLC
16/10/202313:00GlobeNewswire Inc.NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023NASDAQ:NCNANuCana PLC
13/10/202318:30GlobeNewswire Inc.NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023NASDAQ:NCNANuCana PLC
18/09/202314:00GlobeNewswire Inc.NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023NASDAQ:NCNANuCana PLC
16/08/202322:01GlobeNewswire Inc.NuCana Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NCNANuCana PLC
16/06/202314:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NCNANuCana PLC
01/06/202314:00GlobeNewswire Inc.NuCana to Present at the Jefferies Healthcare ConferenceNASDAQ:NCNANuCana PLC
17/05/202322:01GlobeNewswire Inc.NuCana Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NCNANuCana PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NCNA

La tua Cronologia

USOTC
AZGSQ
Aztec Oil and Gas (CE)
BIT
NSCIT0554278
Italy
BIT
UC5F38
Unicredit Bank
BIT
F16414
Vontobel Financial Produ...
BIT
BUND5S
Solactive leveraged shor...
BIT
F34744
Vontobel Financial Produ...
BIT
S28712
Societe Generale Effekten
BIT
F32163
Vontobel Financial Produ...
BIT
F32984
Vontobel Financial Produ...
BIT
EMKT
Amundi MSCI Emerging Mar...
BIT
TRE7
Invesco Us Treasury 3-7 ...
BIT
P1IA36
BNP Paribas Issuance
BIT
UB2Y6R
UniCredit Bank
BIT
PRLAXA
Pierrel
BIT
UC1C4Z
Unicredit Bank
BIT
UV8CNQ
UniCredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci